Clovis Oncology Inc.

(NASDAQ:CLVS) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.

Contact Information

Website: www.clovisoncology.com
Email: bburkart@clovisoncology.com
Main Phone: +1 303 625-5000
Address: 5500 Flatiron Parkway
Address 2: Suite 100
State: CO
City / Town: Boulder
Country: US
Postal Code: 80301

Issuer Information

Exchange: NGS
CEO: Patrick J. Mahaffy
Employees: 429
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A